L-Nutra Europe | ProLon®’s Post

Exciting news in diabetes management! We are proud to share the groundbreaking results from a clinical trial, published in Diabetologia. The study introduces a new approach to Type 2 Diabetes care using the Fasting Mimicking Diet (FMD), suggesting potential outcomes in glycemic control and medication reduction. Key findings: - FMD participants were 8x more likely to reduce medication dosage. - 53% showed improvement in glycemic management. - Support in insulin sensitivity observed. - Positive reductions in weight, BMI, and more. This nutrition-led intervention offers hope for diabetes regression, potentially reducing reliance on medications. Dr. William Hsu, L-Nutra’s Chief Medical Officer, highlights the significance of these findings, indicating a paradigm shift in diabetes management. With over 25 years of development and 32 clinical trials, our company’s FMD program, which is part of our L-Nutra Health medical division, presents a promising path towards managing diabetes without daily lifestyle changes or medication side effects. #DiabetesManagement #FMD #HealthRevolution Joseph Antoun William Hsu, MD Andrea Ghirardi, MBA Michael Lawsky https://lnkd.in/dA4evDQf